

A Common Virus

That May Accelerate Immune Senescence

References

1. Montecino-Rodriguez E, Barent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. *J Clin Invest*. 2013;123(3):958-65.
2. Prlic M, Sacks JA, Bevan MJ. Dissociating markers of senescence and protective ability in memory T cells. *PLoS One*. 2012;7(3):e32576.
3. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. *Nature*. 2006 Apr 13;440(7086):890-5.
4. Janeway CA Jr, Travers P, Walport M, et al. *Immunobiology: The Immune System in Health and Disease*. 5th edition. New York: Garland Science; 2001. "T Cell-Mediated Immunity."
5. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. *Clin Infect Dis*. 2006 Nov 1;43(9):1143-51.
6. Park JH, Yu Q, Erman B, et al. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. *Immunity*. 2004 Aug;21(2):289-302.
7. Takada K, Jameson SC. Naive T cell homeostasis: from awareness of space to a sense of place. *Nat Rev Immunol*. 2009 Dec;9:823-32.
8. Surh CD, Sprent J. Homeostasis of naive and memory T cells. *Immunity*. 2008 Dec 19;29(6):848-62.
9. Weng N. Aging of the immune system: How much can the adaptive immune system adapt? *Immunity*. 2006 May;24(5):495-9.
10. Berard M, Tough DF. Qualitative differences between naive and memory T cells. *Immunology*. Jun 2002; 106(2):127-38.
11. Appay V, Almeida JR, Sauce D, Autran B, Papagno L. Accelerated immune senescence and HIV-1 infection. *Exp Gerontol*. 2007 May;42(5):432-7.
12. Desai S, Landay A. Early immune senescence in HIV disease. *Curr HIV/AIDS Rep*. 2010 Feb;7(1):4-10.
13. Schurich A, Henson SM. The many unknowns concerning the bioenergetics of exhaustion and senescence during chronic viral infection. *Front Immunol*. 2014 Sep 25;5:468.
14. Available at: <http://www.medicalnewstoday.com/articles/280187.php>. Accessed October 20, 2014.
15. Novak Z, Ross SA, Patro RK, et al. Cytomegalovirus strain diversity in seropositive women. *J Clin Microbiol*. 2008 Mar;46(3):882-6.
16. Chou SW. Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors. *J Infect Dis*. 1989 Jul;160(1):11-5.
17. Chandler SH, Handsfield HH, McDougall JK. Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted disease. *J Infect Dis*. 1987 Apr;155(4):655-60.
18. Brunner S, Herndler-Brandstetter D, Weinberger B, Grubeck-Loebenstien B. Persistent viral infections and immune aging. *Ageing Res Rev*. 2011 Jul;10(3):362-9.
19. Ferrando-Martínez S, Ruiz-Mateos E, Hernández A, et al. Age-related deregulation of naive T-cell homeostasis in elderly humans. *Age (Dordr)*. 2011 Jun;33(2):197-207.
20. Kovaïou RD, Weiskirchner I, Keller M, Pfister G, Cioca DP, Grubeck-Loebenstien B. Age-related differences in phenotype and function of CD4+ T cells are due to a phenotypic shift from naive to memory effector CD4+ T cells. *Int Immunol*. 2005 Oct;17(10):1359-66.
21. Available at: <http://emedicine.medscape.com/article/215702-overview>. Accessed October 28, 2014.
22. Wang GC, Kao WH, Murakami P, et al. Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. *Am J Epidemiol*. 2010 May 15;171(10):1144-52.
23. Atzmony L, Halutz O, Avidor B, et al. Incidence of cytomegalovirus-associated thrombosis and its risk factors: a case-control study. *Thromb Res*. 2010 Dec;126(6):e439-43.
24. Savva GM, Pachnio A, Kaul B, et al. Cytomegalovirus infection is associated with increased mortality in the older population. *Aging Cell*. 2013 Jun;12(3):381-7.
25. Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. *Am J Epidemiol*. 2010 Aug 15;172(4): 363-71.
26. Tatum A, Hill AB. Chronic viral infections and immunosenescence, with a focus on CMV. *Open Longevity Science*. 2012;6:33-8.
27. Derhovanessian E, Maier AB, Beck R, et al. Hallmark features of immunosenescence are absent in familial longevity. *J Immunol*. 2010 Oct 15;185(8):4618-24.

28. Voo KS, Peng G, Guo Z, et al. Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation. *Cancer Res.* 2005 Feb 15;65(4):1577-86.
29. Available at: <http://labmed.ucsf.edu/sfghlab/data/tests/63.html>. Accessed October 28, 2014.
30. Available at: https://www.labcorp.com/wps/portal/!ut/p/c1/hY1ZDolwFADP4gFIHwUqfLoAAqVYq2w_hMUQDJtLNHJ6uYCa-ZxMBqVopsfTZ0_mqHPWxSjlGRcJ4xjhkH3sQVYIWvQNqYMNpl98t0D_KnZbujOKEHpMjuZqpAdQ4HAFhgcoQQqw4wHdARxaBm4gKjT--9PxnBnpoaoYtKL0bHK9wn96GB7zy3EPVtlce1VFIra0rytcomuw0XIIIV5FeSMWwmH_Jz9_YxS9Z4osPp95pZQ!!/dl2/d1/L0IJS2FZQSEhL3dMRUJGcUFFQWpNQy9ZSTV5bHchIS83X1VFNFMxSTkzME9HUzlwSVMzTzROMk42NjgwL3ZpZXDUZXN0/?testId=407414. Accessed October 28, 2014.
31. Fessler J, Ficjan A, Duftner C, DeJaco C. The impact of aging on regulatory T-cells. *Front Immunol.* 2013 Aug 6;4:231.
32. Raynor J, Lages CS, Shehata H, Hildeman DA, Chougnnet CA. Homeostasis and function of regulatory T-cells in aging. *Curr Opin Immunol.* 2012 Aug;24(4):482-7.
33. Swain S, Clise-Dwyer K, Haynes L. Homeostasis and the age-associated defect of CD4 T cells. *Semin Immunol.* 2005 Oct;17(5):370-7.
34. Poggi A, Zocchi MR. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. *Arch Immunol Ther Exp (Warsz).* 2006 Sep-Oct;54(5):323-33.
35. Kim R, Emi M, Tanabe K. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. *Cancer Biol Ther.* 2005 Sep;4(9):924-33.
36. Montes CL, Chapoval AI, Nelson J, et al. Tumor-induced senescent T cells with regulatory function: a potential form of tumor immune evasion. *Cancer Res.* 2008 Feb 1;68(3):870-9.
37. Luz Correa B, Ornaghi AP, Cerutti Muller G, et al. The inverted CD4:CD8 ratio is associated with cytomegalovirus, poor cognitive and functional states in older adults. *Neuroimmunomodulat.* 2014 21(4):206-12.
38. Serrano-Villar S, Pérez-Elías MJ, Dronda F, et al. Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio. *PLoS One.* 2014 Jan 30;9(1):e85798.
39. Blankenberg S, Rupprecht HJ, Bickel C, et al. Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. *Circulation.* 2001 Jun 19;103(24):2915-21.
40. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. *JAMA.* 1989 Jun 23-30;261(24):3561-6.
41. Hendrix MG, Dormans PH, Kitslaar P, Bosman F, Bruggeman CA. The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and nonatherosclerotic patients. *Am J Pathol.* 1989 May;134(5):1151-7.
42. Bentz GL, Yurochko AD. Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta 1 and beta 3 integrins. *Proc Natl Acad Sci USA.* 2008 Apr 8;105(14):5531-6.
43. Bolovan-Fritts CA, Trout RN, Spector SA. High T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage. *Blood.* 2007 Sep 15;110(6):1857-63.
44. Rahbar A, Söderberg-Nauclér C. Human cytomegalovirus infection of endothelial cells triggers platelet adhesion and aggregation. *J Virol.* 2005 Feb;79(4):2211-20.
45. Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. *Am J Pathol.* 1990 Jan;136(1):23-8.
46. Adam E, Melnick JL, Probstfield JL, et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. *Lancet.* 1987 Aug 8;2(8554):291-3.
47. Harley CB, Liu W, Blasco M, et al. A natural product telomerase activator as part of a health maintenance program. *Rejuvenation Res.* 2011 Feb;14(1):45-56.
48. Dowd JB, Bosch JA, Steptoe A, et al. Cytomegalovirus is associated with reduced telomerase activity in the Whitehall II cohort. *Exp Gerontol.* 2013 Apr;48(4):385-90.
49. Valenzuela HF, Effros RB. Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. *Clin Immunol.* 2002 Nov;105(2):117-25.
50. van de Berg PJ, Griffiths SJ, Yong SL, et al. Cytomegalovirus infection reduces telomere length of the circulating T cell pool. *J Immunol.* 2010 Apr 1;184(7):3417-23.
51. Fletcher JM, Vukmanovic-Stejic M, Dunne PJ, et al. Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion. *J Immunol.* 2005 Dec 15;175(12):8218-25.

52. Meijers RW, Litjens NH, de Wit EA, et al. Cytomegalovirus contributes partly to uraemia-associated premature immunological ageing of the T cell compartment. *Clin Exp Immunol*. 2013 Dec;174(3):424-32.
53. Sansoni P, Vescovini R, Fagnoni F, et al. The immune system in extreme longevity. *Exp Gerontol*. 2008 Feb;43(2):61-5.
54. Mekker A, Tchang VS, Haeberli L, Oxenius A, Trkola A, Karrer U. Immune senescence: relative contributions of age and cytomegalovirus infection. *PLoS Pathog*. 2012 8(8): e1002850.
55. Rahbar A, Orrego A, Peredo I, et al. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. *J Clin Virol*. 2013 May;57(1):36-42.
56. Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. *NEJM*. 2013 Sep;369(10):985-6.
57. Brum S, Nolasco F, Sousa J, et al. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. *Transplant Proc*. 2008 Apr;40(3):752-4.
58. Ar MC, Ozbalak M, Tuzuner N, et al. Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases. *Transplant Proc*. 2009 Jun;41(5):1648-53.
59. Hazeldine J, Lord JM. The impact of ageing on natural killer cell function and potential consequences for health in older adults. *Ageing Res Rev*. 2013 Sep;12(4):1069-78.
60. van Baarle D, Tsegaye A, Miedema F, Akbar A. Significance of senescence for virus-specific memory T cell responses: rapid ageing during chronic stimulation of the immune system. *Immunol Lett*. 2005 Feb 15;97(1):19-29.
61. Effros RB, Pawelec G. Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? *Immunol Today*. 1997 Sep;18(9):450-4.
62. Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann N Y Acad Sci*. 2000 Jun;908:244-54.
63. Chou JP, Effros RB. T cell replicative senescence in human aging. *Curr Pharm Des*. 2013;19(9):1680-98.
64. Wikby A, Maxson P, Olsson J, Johansson B, Ferguson FG. Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the Swedish longitudinal OCTO-immune study. *Mech Ageing Dev*. 1998 May 15;102(2-3):187-98.
65. Ferguson FG, Wikby A, Maxson P, Olsson J, Johansson B. Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors. *J Gerontol A Biol Sci Med Sci*. 1995 Nov;50(6):B378-82.
66. Kang I, Hong MS, Nolasco H, et al. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. *J Immunol*. 2004 Jul 1;173(1): 673-81.
67. Grubeck-Loebenstien B, Della Bella S, Iorio AM, Michel JP, Pawelec G, Solana R. Immunosenescence and vaccine failure in the elderly. *Ageing Clin Exp Res*. 2009 Jun;21(3):201-9.
68. Saurwein-Teissl M, Lung TL, Marx F, et al. Lack of antibody production following immunization in old age: association with CD8(+)/CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. *J Immunol*. 2002 Jun 1;168(11):5893-9.
69. Koskinen P, Lemström K, Bruggeman C, Lautenschlager I, Häyry P. Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall. A possible linkage with enhanced allograft arteriosclerosis. *Am J Pathol*. 1994 Jan;144(1):41-50.
70. Safaie N, Ghotaslou R, Montazer Ghaem H. Seroprevalence of cytomegalovirus in patients with and without coronary artery diseases at Madani Heart Center, Iran. *Acta Med Iran*. 2010 Nov-Dec;48(6):403-6.
71. Grahame-Clarke C, Chan NN, Andrew D, et al. Human cytomegalovirus seropositivity is associated with impaired vascular function. *Circulation*. 2003 Aug 12;108(6):678-83.
72. Crumpacker CS. Invited commentary: human cytomegalovirus, inflammation, cardiovascular disease, and mortality. *Am J Epidemiol*. 2010 Aug 15;172(4):372-4.
73. Cheng J, Ke Q, Jin Z, et al. Cytomegalovirus infection causes an increase of arterial blood pressure. *PLoS Pathog*. 2009 May;5(5):e1000427.
74. Schmidt D, Martens PB, Weyand CM, Goronzy JJ. The repertoire of CD4+ CD28 T cells in rheumatoid arthritis. *Mol Med*. 1996 Sep;2(5):608-18.
75. Schirmer M, Goldberger C, Würzner R, et al. Circulating cytotoxic CD8(+)/CD28(-) T cells in ankylosing spondylitis. *Arthritis Res*. 2002 4(1):71-6.
76. Terrazzini N, Bajwa M, Vita S, et al. A novel cytomegalovirus-induced regulatory-type T-cell subset increases in size during older life and links virus-specific immunity to vascular pathology. *J Infect Dis*. 2014 May 1;209(9):1382-92.
77. Barnes LL, Capuano AW, Aiello AE, et al. Cytomegalovirus infection and risk of Alzheimer's disease in older blacks and whites. *J Infect Dis*. 2014 Aug 8.
78. Jones A, McCurdy JD, Loftus EV Jr, et al. Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus. *Clin Gastroenterol Hepatol*. 2014 Oct 2.
79. Chiba M, Abe T, Tsuda S, Ono I. Cytomegalovirus infection associated with onset of ulcerative colitis. *BMC Res Notes*. 2013 Feb 2;6:40.
80. Kedhar SR, Jabs DA. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. *Herpes*. 2007 Dec;14(3):66-71.

81. Riddell SR. Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts. *Semin Respir Infect.* 1995 Dec;10(4):199-208.
82. Solana R, Campos C, Pera A, Tarazona R. Shaping of NK cell subsets by aging. *Curr Opin Immunol.* 2014 Aug;29:56-61.
83. Sinzger C, Digel M, Jahn G. Cytomegalovirus cell tropism. *Curr Top Microbiol Immunol.* 2008;325:63-83.
84. Wang D, Ma Y, Wang J, Liu X, Fang M. Natural killer cells in innate defense against infective pathogens. *J Clin Cell Immunol.* 2013; S13:006.
85. Brandstadter JD, Yang Y. Natural killer cell responses to viral infection. *J Innate Immun.* 2011 3(3):274-9.
86. Orange JS. Human natural killer cell deficiencies and susceptibility to infection. *Microbes Infect.* 2002 Dec;4(15):1545-58.
87. Terunuma H, Deng X, Dewan Z, Fujimoto S, Yamamoto N. Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. *Int Rev Immunol.* 2008 27(3):93-110.
88. Tarazona R, Gayoso I, Alonso C, et al. NK cells in human ageing. In *Handbook on Immunosenescence.* Netherlands: Springer;2009:531-44.
89. Albright JW, Albright JF. Age-associated decline in natural killer (NK) activity reflects primarily a defect in function of NK cells. *Mech Ageing Dev.* 1985 Sep;31(3):295-306.
90. Hazeldine J, Hampson P, Lord JM. Reduced release and binding of perforin at the immunological synapse underlies the age-related decline in natural killer cell cytotoxicity. *Aging Cell.* 2012 Oct;11(5):751-9.
91. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. *J Exp Med.* 2005 Jun 20;201(12):1973-85.
92. Sanchez-Correa B, Morgado S, Gayoso I, et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. *Cancer Immunol Immunother.* 2011 Aug;60(8):1195-205.
93. Bruminhent J, Razonable RR. Management of cytomegalovirus infection and disease in liver transplant recipients. *World J Hepatol.* 2014 Jun 27;6(6):370-83.
94. Pourgheysari B, Bruton R, Parry H, et al. The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire. *Blood.* 2010 Oct 21;116(16):2968-74.
95. Schütt P, Brandhorst D, Stellberg W, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. *Leuk Lymphoma.* 2006 Aug;47(8):1570-82.
96. Dodd CL, Winkler JR, Heinic GS, Daniels TE, Yee K, Greenspan D. Cytomegalovirus infection presenting as acute periodontal infection in a patient infected with the human immunodeficiency virus. *J Clin Periodontol.* 1993 Apr;20(4):282-5.
97. Available at: <http://www.nlm.nih.gov/medlineplus/ency/article/000665.htm>. Accessed October 28, 2014.
98. Rodriguez-Barradas MC, Stool E, Musher DM, et al. Diagnosing and treating cytomegalovirus pneumonia in patients with AIDS. *Clin Infect Dis.* 1996 Jul;23(1):76-81.
99. Rosa C, Limaye AP, Krishnan A, Blumstein G, Longmate J, Diamond DJ. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. *Transpl Int.* 2011 Sep;24(9):920-31.
100. Baryawno N, Rahbar A, Wolmer-Solberg N, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. *J Clin Invest.* 2011 Oct;121(10):4043-55.
101. Stragliotto G, Rahbar A, Solberg NW, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. *Int J Cancer.* 2013 Sep 1;133(5):1204-13.
102. Yasuoka A. Anti-cytomegaloviral drugs *Nihon Rinsho.* 2012 Apr;70(4):564-7.
103. Iversen AC, Norris PS, Ware CF, Benedict CA. Human NK cells inhibit cytomegalovirus replication through a noncytolytic mechanism involving lymphotoxin-dependent induction of IFN-beta. *J Immunol.* 2005 Dec 1;175(11):7568-74.
104. Daiwa Pharmaceutical. NK cell immunomodulatory function by modified arabinosyloxylan rice bran (MGN-3/Biobran) at low concentration (500 mg/day = 7 mg/kg/day). 2012. Supplier unpublished or internal study.
105. Cholujova D, Jakubikova J, Czako B, et al. MGN-3 arabinosyloxylan rice bran modulates innate immunity in multiple myeloma patients. *Cancer Immunol Immunother.* 2013 Mar;62(3):437-45.
106. Bang MH, Van Riep T, Thinh NT, et al. Arabinosyloxylan rice bran (MGN-3) enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: a three-year randomized clinical trial. *Anticancer Res.* 2010 Dec;30(12):5145-51.
107. Brockmeyer NH, Kreuzfelder E, Guttman W, Mertins L, Goos M, Ohnhaus EE. Cimetidine and the immuno-response in healthy volunteers. *J Invest Dermatol.* 1989 Dec;93(6):757-61.
108. Horvath J, Sinkovics JG. Adoptive immunotherapy with activated peripheral blood lymphocytes. *Leukemia.* 1994 Apr;8 Suppl 1:S121-6.
109. Zeng P, Xiao J, Lei Y. Cell-mediated immune function in NPC patients treated with cimetidine. *Zhonghua Zhong Liu Za Zhi.* 1995 May;17(3):223-5.

110. Kikuchi Y, Kizawa I, Oomori K, et al. Effects of cimetidine on interleukin-2 production by peripheral blood lymphocytes in advanced ovarian carcinoma. *Eur J Cancer Clin Oncol*. 1988 Jul;24(7):1185-90.
111. Shen Y, Qu QX, Zhu YB, Zhang XG. Analysis of CD8+CD28- T-regulatory cells in gastric cancer patients. *J Immunoassay Immunochem*. 2012;33(2):149-55.
112. Ha TY. The role of regulatory T cells in cancer. *Immune Netw*. 2009 Dec;9(6):209-35.
113. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. *Cancer Res*. 2006 Jun 1;66(11):5527-36.
114. Wikby A, Månsson IA, Johansson B, Strindhall J, Nilsson SE. The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20-100 years of age. *Biogerontology*. 2008 Oct;9(5):299-308.
115. Strindhall J, Skog M, Ernerudh J, et al. The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish HEXA immune study. *Age (Dordr)*. 2013 Jun;35(3):985-91.
116. Serrano-Villar S, Moreno S, Fuentes-Ferrer M, et al. The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery. *HIV Med*. 2014 Jan;15(1):40-9.
117. Ohara T, Takahashi M, Yamanaka H, Yamamoto Y, Shimada A, Nakaho T. Serum lactate dehydrogenase and CD4+/CD8+ lymphocyte ratio predict survival in terminally ill cancer patients. *Gan To Kagaku Ryoho*. 2002 Oct;29(10):1779-83.
118. Sevcíková L, Hunáková L, Chorváth B, Turzová M, Boljesíková E. T-lymphocyte subsets (CD4/CD8 ratio) in breast cancer patients. *Neoplasma*. 1992 39(4):219-22.
119. Yager EJ, Ahmed M, Lanzer K, Randall TD, Woodland DL, Blackman MA. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. *J Exp Med*. 2008 Mar 17;205(3):711-23.
120. Cosmi L, Maggi L, Santarlaschi V, Liotta F, Annunziato F. T helper cells plasticity in inflammation. *Cytometry A*. 2014 Jan;85(1):36-42.
121. Krüger S, Schroers R, Rooney CM, Gahn B, Chen SY. Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. *J Immunother*. 2003 May-Jun;26(3):212-21.
122. Scriba TJ, Zhang HT, Brown HL, et al. HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. *J Clin Invest*. 2005 Feb;115(2):443-50.
123. Fahey JL, Prince H, Weaver M, et al. Quantitative changes in T helper or T regulatory/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. *Am J Med*. 1984 Jan;76(1):95-100.
124. Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, Zheng H, Lu Z, Freedberg KA, Losina E. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. *J Acquir Immune Defic Syndr*. 2006 Aug 1;42(4):464-9.
125. Zhang K, Ma X, He W, et al. Extracts of *Cistanche deserticola* Can Antagonize Immunosenescence and Extend Life Span in Senescence-Accelerated Mouse Prone 8 (SAM-P8) Mice. *Evid Based Complement Alternat Med*. 2014 601383.
126. Kilgour AH, Firth C, Harrison R, et al. Seropositivity for CMV and IL-6 levels are associated with grip strength and muscle size in the elderly. *Immun Ageing*. 2013 Aug 13;10(1):33.
127. Abdellaoui A, Al-Khaffaf H. C-reactive protein (CRP) as a marker in peripheral vascular disease. *Eur J Vasc Endovasc Surg*. 2007 Jul;34(1):18-22.
128. Strandberg TE, Tilvis RS. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. *Arterioscler Thromb Vasc Biol*. 2000 Apr;20(4):1057-60.
129. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. *Arch Neurol*. 2004 May;61(5):668-72.
130. Kravitz BA, Corrada MM, Kawas CH. Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. *Alzheimers Dement*. 2009 Jul;5(4):318-23.
131. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. *J Clin Oncol*. 2009 May 1;27(13):2217-24.
132. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. *JAMA*. 2004 Feb 4;291(5):585-90.
133. Giltay EJ, Haider A, Saad F, Gooren LJ. C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation. *Andrologia*. 2008 Dec;40(6):398-400.
134. Wickramatilake CM, Mohideen MR, Withanawasam BP, Pathirana C. Testosterone and high-sensitive C-reactive protein in coronary artery disease patients awaiting coronary artery bypass graft. *Andrologia*. 2014 May 9.
135. Helaly MA, Daoud E, El-Mashad N. Does the serum testosterone level have a relation to coronary artery disease in elderly men? *Curr Gerontol Geriatr Res*. 2011 791765.
136. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the

- metabolic syndrome: the double-blinded placebo-controlled Moscow study. *Clin Endocrinol (Oxf)*. 2010 Nov;73(5):602-12.
137. Available at: http://www.gsk.com.au/resources.ashx/prescriptionmedicinesproductschilddataproinfo/843/FileName/1BF361428971B19DA2CEF2E3EAD3BE09/PI_Tagamet.pdf. Accessed October 21, 2014.
 138. Available at: <http://www.rxlist.com/tagamet-drug/side-effects-interactions.htm>. Accessed October 21, 2014.
 139. Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. *Gastroenterology*. 1991 Dec;101(6):1680-91.
 140. Krenzelok EP. Sildenafil: clinical toxicology profile. *J Toxicol Clin Toxicol*. 2000;38(6):645-51.
 141. Greene W. Drug interactions involving cimetidine--mechanisms, documentation, implications. *Q Rev Drug Metab Drug Interact*. 1984;5(1):25-51.
 142. Ruffalo RL, Thompson JF, Segal JL. Diazepam-cimetidine drug interaction: a clinically significant effect. *South Med J*. 1981 Sep;74(9):1075-8.
 143. Villeneuve JP, Fortunet-Fouin H, Arsène D. Cimetidine kinetics and dynamics in patients with severe liver disease. *Hepatology*. 1983 Nov-Dec;3(6):923-7.
 144. Ben-Joseph R, Segal R, Russell WL. Risk for adverse events among patients receiving intravenous histamine2-receptor antagonists. *Ann Pharmacother*. 1993 Dec;27(12):1532-7.
 145. Jenike MA. Cimetidine in elderly patients: review of uses and risks. *J Am Geriatr Soc*. 1982 Mar;30(3):170-3.
 146. Bell WR, Anderson KC, Noe DA, Silver BA. Reduction in the plasma clearance rate of warfarin induced by cimetidine. *Arch Intern Med*. 1986 Dec;146(12):2325-8.
 147. Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. *Br J Clin Pharmacol*. 2002;Suppl 1:31S-36S.
 148. Barber SG. Male sexual dysfunction and cimetidine. *Br Med J*. 1979 Apr 28;1(6171):1147.
 149. Peden NR, Cargill JM, Browning MC, Saunders JH, Wormsley KG. Male sexual dysfunction during treatment with cimetidine. *Br Med J*. 1979 Mar 10;1(6164):659.
 150. Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. *Expert Opin Drug Saf*. 2012 Sep;11(5): 779-95.
 151. Jensen RT, Collen MJ, Pandol SJ, et al. Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. *N Engl J Med*. 1983 Apr 14;308(15):883-7.
 152. Spence RW, Celestin. Gynaecomastia associated with cimetidine. *Gut*. 1979; 20(2):154-7.
 153. Available at: <http://www.rxlist.com/tagamet-drug/side-effects-interactions.htm>. Accessed October 21, 2014.
 154. Sivelse PC, Underwood AH, Jelly JA. The effects of histamine H2 receptor antagonists on androgen action in vivo and dihydrotestosterone binding to the rat prostate androgen receptor in vitro. *Biochem Pharmacol*. 1982 Mar 1;31(5):677-84.
 155. Barbara L, Corinaldesi R, Pasquali R, Raiti C, Zurita J, Stanghellini V. Endocrine effects of the H2-receptor antagonists cimetidine and ranitidine. *Int J Tissue React*. 1983 5(4):387-92.